Stockwinners Market Radar for July 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:20 EDT Electronic Arts CFO sells $435K in common stock - In a regulatory filing, Electronic Arts disclosed that its CFO Stuart Canfield sold 3K shares of common stock on July 11th in a total transaction size of $435K.

19:36 EDT Box CFO sells $324.6K in common stock - In a regulatory filing, Box disclosed that its CFO Dylan Smith sold 13K shares of common stock on July 10th in a total transaction size of $324.6K.

19:34 EDT FS Bancorp raises quarterly dividend to 27c per share from 26c - The cash dividend will be paid on August 21, 2024 to shareholders of record as of August 7, 2024.

19:30 EDT Autodesk COO sells $4.9M in common stock - In a regulatory filing, Autodesk disclosed that its COO Steven Blum sold 19.7K shares of common stock on July 11th in a total transaction size of $4.9M.

18:46 EDT Immtech's efti and Merck's Keytruda combination show positive Phase 2b results - Immutep (IMM) announced positive results from Cohort B of the TACTI-003 Phase IIb trial evaluating eftilagimod alfa - efti - in combination with Merck's (MRK) anti-PD-1 therapy Keytruda - pembrolizumab - as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, or 1L HNSCC, patients with negative PD-L1 expression. The investigational immuno-oncology combination utilising efti and Keytruda achieved an objective response rateof 35.5% - 11 of 31 evaluable patients - and a disease control rate of 58.1% in 1L HNSCC patients whose tumours do not express PD-L1. These results are among the highest recorded for a chemotherapy-free approach in negative PD-L1 patients and compare favourably to a historical control of 5.4% ORR and 32.4% DCR from anti-PD-1 monotherapy. Additionally, the IO combination attained a high complete response rate of 9.7%, which compares favourably to a historical control of 0% from anti-PD-1 monotherapy in 1L HNSCC patients with a CPS less than1. Durability of responses is tracking well as has been seen in other clinical trials when efti is combined with Keytruda. The combination also continues to have a favourable safety profile with no new safety signals observed. Immutep will discuss the path forward with regulatory agencies.

18:16 EDT Estee Lauder CFO Travis to retire - The Estee Lauder Companies announced that Tracey T. Travis, Executive Vice President and Chief Financial Officer, has decided to retire, effective June 30, 2025, after more than twelve years of exemplary leadership and service at the company. A successor for the CFO role has been identified and will be named in the coming weeks. Tracey will work closely with this person to ensure a smooth and successful transition. "Tracey has been an invaluable business partner and a trusted advisor to me, our executives and Board of Directors, as well as a mentor and role model to many across our organization," said Fabrizio Freda, President and Chief Executive Officer. "She has built and led a robust, integrated Global Finance & Strategy organization that has served as a valued business partner across the company and has helped to optimize delivery of our financial plans. Her financial acumen, discipline, and operational excellence have been essential to our company's growth, and so many areas of our organization have her valuable imprint on them."

18:08 EDT Alta Equipment Group joins Cyngn dealer network - Earlier this morning, the company announced: "Cyngn announced the expansion of its dealer network to include Alta Equipment Group. The purveyor of both construction and material handling equipment will begin selling Cyngn's autonomous DriveMod Tugger. The DriveMod Tugger bundles Cyngn's autonomous vehicle technology with Motrec's MT-160. This announcement follows two significant milestones for Cyngn: the launch of the DriveMod Tugger and the Cyngn Dealer Network in the fall of 2023. Cyngn has continued to grow its Dealer Network, including the recent addition of RobotLab, a robotics company with over 10,000 robots deployed. Alta's decision to join Cyngn's Dealer Network came after a successful summit at Cyngn's Menlo Park headquarters, where key decision-makers experienced the company's autonomous mobile robots firsthand. Cyngn plans to continue expanding its Dealer Network by adding more distribution and integration partners in the future." Shares of Cyngn closed up 85% in regular trading today at $7.33 per share.

17:37 EDT Ultra Clean CEO Scholhamer sells 26,608 common shares - In a regulatory filing, Ultra Clean Holdings CEO James Scholhamer disclosed the sale of 26,608 common shares of the company on July 9 at a price of $55.10 per share.

17:32 EDT Nvidia director sells $104M in common stock as part of option exercise - In a regulatory filing, Nvidia disclosed that its director Mark Stevens sold 785K shares of common stock on July 9th as part of option exercise in a total transaction size of $104M.

17:11 EDT Lockheed Martin awarded $251.48M Army contract modification - Sikorsky, a Lockheed Martin company, was awarded a $251.48M modification to a contract for UH-60M aircraft. Work will be performed in Stratford, Connecticut, with an estimated completion date of June 30, 2027. FY24 aircraft procurement, Army funds; and Foreign Military Sales funds in the amount of $251.48M, were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:05 EDT Braze launches Braze Data Platform - This morning, the company announced: "Braze announced the launch of the Braze Data Platform, a comprehensive, composable set of data capabilities and partner integrations designed to streamline data unification, activation, and distribution, empowering marketers to create memorable, relevant customer engagements with Braze. Unified and contextualized data is crucial for creating customer-centric marketing experiences, and brands that fail to deliver risk losing consumer attention, loyalty, and revenue. Marketers are struggling to integrate and make sense of data for customer engagement with excessive data collection: Braze research found that only 24% of brands are mapping customer behavior and sentiment, and only 6% are using this data to inform their product and brand approach. Built with flexibility, interoperability, and modularity in mind, the Braze Data Platform helps brands easily integrate and leverage their data, regardless of their preferred technologies and workflows."

17:01 EDT SilverCrest Metals reports 15,303 gold ounces recovered in Q2 - Reports 1.46M silver, 2.68M silver equivalent ounces recovered in Q2. N. Eric Fier, CEO commented, "We are pleased to deliver another strong quarter in regards to production, grades and recoveries at the Las Chispas Operation. Sales in the first half of 2024 of 5.19 million AgEq ounces position us well to deliver on our 2024 annual sales guidance of 9.8 to 10.2 million ounces AgEq. Silver equivalent processed grades of 765 grams per tonne and recoveries of 98.4% tracked above plan, with silver recoveries setting another record for the operation. This, combined with substantial increases in gold and silver prices in the quarter, drove record revenues and a return to growth of treasury assets in the quarter, despite planned higher sustaining capital expenditures. Also, during the quarter our bullion holdings grew 20% to $24.0 million through the addition of 400 ounces of gold and increased metal prices. Treasury assets increased 34%, to total $122.3 million at the end of the quarter, including $98.3 million in cash. We continue to benefit from having two mining contractors at site, with our financial strength allowing for greater operational flexibility in the ramp-up, including continued management of our stockpiles. We look forward to providing more details of our operational and financial performance in early August."

17:00 EDT Lazard chairman sells $3.0M in common stock - In a regulatory filing, Lazard disclosed that its executive chairman Kenneth Jacobs sold 74.4K shares of common stock on July 9th in a total transaction size of $3.0M.

16:30 EDT Quaker Houghton breaks ground on new manufacturing facility in China - Quaker Houghton celebrated breaking ground on its new state-of-the-art manufacturing facility in Zhangjiagang, China. The new facility will expand the Company's production capabilities to support the growth of its customers and the Company in the Asia-Pacific region. The Zhangjiagang, China facility, which combines industry-leading technology with Quaker Houghton's long history of manufacturing excellence and safety, is expected to be operational by the second quarter of 2026.

16:20 EDT DHT Holdings provides Q2 business update - DHT Holdings provided the following business update: "For the second quarter of 2024, the Company estimates time charter equivalent earnings for its fleet at $49,100 per day, comprising of $52,700 per day for the Company's VLCCs operating in the spot market and $36,400 per day for the Company's VLCCs on time-charter. The estimated time charter equivalent earnings are based on 2,114 revenue days for the second quarter, of which 1,644 days are spot days. Thus far in the third quarter of 2024, 48% of the available spot days have been booked at an average rate of $45,600 per day on a discharge-to-discharge basis. 61% of the available revenue days, spot and time-charter days combined, have been booked at an average rate of $42,300 per day. In the second quarter of 2024, the Company entered into a one-year time charter contract with a refining company for DHT Europe, built 2007. The time charter contract has a rate of $49,500 per day and the vessel is intended to trade in the Atlantic basin, servicing a European refinery. As previously announced, the Company has entered into agreements to build four large VLCCs with originally expected delivery between April and December 2026. The expected delivery has been expedited, hence increasing revenue days in 2026. We expect the first vessel to be delivered in February, the second vessel in April, the third vessel in May and the fourth and final vessel is expected to be delivered in July 2026."

16:17 EDT Tupperware Brands announces CFO Mariela Matute to resign - In a regulatory filing, Tupperware Brands disclosed that on July 5, Mariela Matute, Executive Vice President & CFO of Tupperware Brands, informed the company of her intention to resign from her position, effective July 31. Matute's decision to resign from the company was not due to any disagreement with the company, its management or the Board of Directors on any matter relating to the company's operations, policies or practices.

16:17 EDT Bonnell Aluminum commends Biden administration's proclamation on trade benefits - Bonnell Aluminum, a subsidiary of Tredegar Corporation, commends the Biden administration's proclamation to strengthen the rules to qualify for trade benefits between the U.S. and Mexico. "Under this proclamation, for aluminum to qualify for relief from the Section 232 Tariff, the "smelted and cast" requirement prohibits preferential treatment for imports where the primary country of smelt, secondary country of smelt, or country of most recent cast was Belarus, China, Russia, or Iran," the company said. "This negotiated requirement recognizes the inherent unfair trade practice which occurs when U.S. trading partners can process subsidized metal from countries like China and Russia."

16:12 EDT Diana Shipping announces time charter contract for m/v Atalandi with Cargill - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International, Geneva, for one of its Ice Class Panamax dry bulk vessels, the m/v Atalandi. The gross charter rate is US$14,600 per day, minus a 4.75% commission paid to third parties, for a period until minimum June 1, 2025 up to maximum July 31, 2025. The charter is expected to commence on July 19. The "Atalandi" is a 77,529 dwt Ice Class Panamax dry bulk vessel built in 2014. The employment of "Atalandi" is anticipated to generate approximately US$4.57 million of gross revenue for the minimum scheduled period of the time charter.

16:09 EDT Roku names Louise Pentland as General Counsel - Roku (ROKU) announced that Louise Pentland will join the company as Senior Vice President and General Counsel, effective July 23. Pentland will report to Anthony Wood, Founder and CEO, and will succeed current SVP and General Counsel Stephen Kay, who is retiring in November. Pentland joins Roku from The Walt Disney Company (DIS), where she has been Executive Vice President and Chief Counsel for Disney Experiences and Products. In this role, she oversees all legal and regulatory matters for the segment's businesses, which include its global theme park destinations, cruise operations, global consumer products operations, and e-commerce platform.

16:08 EDT CoStar Group names Rich Simonelli as Head of Investor Relations - CoStar Group announced the appointment of Rich Simonelli as Head of Investor Relations and Cyndi Eakin as Chief Accounting Officer. Each will report to Chris Lown, Chief Financial Officer of CoStar Group. Simonelli, who previously held a similar role at CoStar Group for nine years, will rejoin the company from national real estate brokerage Compass, where he served as Senior Vice President, Investor Relations. Eakin, who previously served as CoStar Group's Controller, most recently served as Head of Investor Relations, working with investors, shareholders and analysts to convey CoStar Group's performance, business strategy, and strategic positioning. In her new role, Eakin will be responsible for corporate accounting, revenue reporting, tax compliance, technical accounting and policy and financial reporting. Eakin's

16:06 EDT Masimo director Brennan urges shareholders to support cultural reset - Politan Capital Management, an 8.9% shareholder of Masimo, shared a statement from Michelle Brennan, an independent director of Masimo: "When I was approached last year by an executive search firm about the opportunity to potentially serve on Masimo's Board of Directors, I was immediately intrigued. Although I had no pre-existing relationship with Politan, I was very familiar with Masimo and its reputation in the sector given my time spent overseeing multi-billion-dollar global medical device businesses for Johnson & Johnson. As I did more of my own research, it became clear to me that Masimo was a company with vast potential - which ultimately led me to accept the role as an independent nominee. After shareholders voiced their desire for change and elected Quentin and me to the Board, I was optimistic that I would be able to work constructively with the other independent directors. However, when I shared a standard list of onboarding questions and requested data that I had found useful in my other board roles, I was rebuffed. I was told to be patient, and that eventually I would receive the information I needed to do my job as a director. After two months, I was told to stop asking. Masimo's boardroom is not like any other I have experienced. There is no budget process. There is no belief that directors need to be adequately informed about, or provide oversight in relation to, regulatory investigations like the ones opened by the DOJ and the SEC at Masimo. And, most troublingly, there is a deep-seated belief among Mr. Kiani's hand-picked directors that the desire to actively oversee management is equivalent to disloyalty. Specifically, the status quo is to "trust and believe" whatever Mr. Kiani says and not ask questions beyond the information he provides - even when there is an apparent disconnect between what may be best for Mr. Kiani and what is best for shareholders. Nowhere has this been more apparent than during the potential transaction process to separate the Consumer Business, during which directors received material information for the first time via Mr. Kiani's media appearances. The bottom line is that my experience has led me to believe that the Board is unable to carry out its basic functions because it is essentially kept in the dark. As a result, all of Masimo's stakeholders have suffered. Shareholders have repeatedly seen results that miss expectations and have cost the Company its credibility with the financial community while driving down the share price. Employees have to deal with the distraction of two successive proxy contests, bonus cuts and coercion by leadership to demonstrate their "support" for Mr. Kiani. Patients are not the top priority they should be, as the Company invests in unnecessary areas and faces inquiries into recall processes. Masimo has the market position and leading technology to be a growth business. It's my belief that our responsibility as directors is to help make that a reality, by continuing to invest in R&D and enhancing productivity. This is the type of transformation I led at Johnson & Johnson when I successfully returned multiple medical device businesses that had stagnated to above market growth, and it is what I am committed to achieving at Masimo. Ironically, Mr. Kiani and his affiliated directors have made the fear of "disruption" a central theme of their campaign to maintain the status quo. This rings hollow to me. As an experienced operator, I know that the continuation of the problems listed above - in addition to the notion that if Mr. Kiani's affiliated directors view him as "irreplaceable," they will never feel like they can hold him to account - represent massively greater risks than a majority of independent directors sitting on the Board. Over the last few months, I have had an opportunity to get to know Darlene Solomon and Bill Jellison. They are the type of objective, qualified and seasoned directors Masimo needs - particularly at this critical juncture as the Company advances the separation of the Consumer Business. The myriad financial hurdles and nuanced IP transfers that need to be navigated in order to ensure any potential transaction maximizes value for shareholders, while positioning Masimo for success over the long term, are areas where Darlene and Bill have direct expertise. The Board would be lucky to have them. I continue to believe Masimo's best days are in front of it. This is why I urge shareholders to support further change and true independent oversight at Masimo's upcoming 2024 Annual Meeting."

16:03 EDT Concord Medical to implement ADS ratio change - Concord Medical plans to change the ratio of its American depositary shares - ADSs - to Class A ordinary shares from the current ADS Ratio of one ADS representing three Class A ordinary shares to a new ADS Ratio of one ADS representing 30 Class A ordinary shares. The company anticipates that the change in the ADS Ratio will be effective on July 30. The ADSs of Concord Medical will continue to be traded on the New York Stock Exchange under the symbol "CCM." For the ADS holders of Concord Medical, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split. The change in the ADS Ratio will have no impact on the underlying Class A ordinary shares of Concord Medical, and no Class A ordinary shares will be issued or cancelled in connection with the change in the ADS Ratio.

16:00 EDT Global Partner Acquisition Corp II trading resumes

15:01 EDT Department of Labor confirms $12M settlement with Dollar General - The Department of Labor confirmed that its Occupational Safety and Health Administration has entered into a corporate-wide settlement with Dollar General and its retail subsidiaries "to make significant workplace safety improvements in stores nationwide." Dollar General agreed to pay $12M in penalties and implement corporate-wide "changes that make the safety of its employees a priority," the agency said in a statement. The improvements include establishing and maintaining an expanded safety structure and a robust safety and health management system, including hiring additional safety managers, significantly reducing inventory and increasing stocking efficiency to prevent blocked exits and unsafe material storage, providing safety and health training to both leadership and non-managerial employees, and developing a safety and health committee and encouraging employee participation. The agreement also requires Dollar General to ensure prompt abatement of any future violations related to blocked exits, access to fire extinguishers and electrical panels, and improper material storage at its stores during the agreement term. The company must correct such hazards - generally within 48 hours - and submit proof they corrected hazards. Failure to do so subjects Dollar General to monetary assessments of $100,000 per day of violation, up to $500,000, as well as OSHA inspection and enforcement actions. Reference Link

14:01 EDT Cummins awarded $75M for zero-emissions manufacturing from DOE - Cummins announced that the company has been awarded $75M to convert approximately 360,000 sq. ft. of existing manufacturing space at its Columbus ,Indiana Engine Plant for zero-emissions components and electric powertrain systems. "The $75 million grant is the largest federal grant ever awarded solely to Cummins and is part of the appropriations related to the Inflation Reduction Act. Cummins will match the grant and invest $75 million for a total of $150 million to convert the space and expand production of battery packs, powertrain systems and other battery-electric vehicle components for Accelera by Cummins, the company's zero-emissions business segment. To support this additional manufacturing capacity, Cummins anticipates adding approximately 250 full-time jobs, with opportunities for the plant's existing workforce to transition to many of these positions over time," the company stated.

13:07 EDT Five9 jumps 6% after Reuters says activist pushing company to explore sale

13:05 EDT Teck Resources reports completion of steelmaking coal unit to Glencore - Teck Resources Limited (TECK) announced that it has completed the sale of its remaining 77% interest in the steelmaking coal business to Glencore plc (GLNCY). Teck received total cash proceeds of $7.3B, subject to customary closing adjustments.

12:41 EDT EPA, DOJ announce $241.5M settlement with Marathon Oil - The Environmental Protection Agency and Department of Justice announced a settlement with Marathon Oil Company resolving Clean Air Act violations at the company's oil and gas production operations on the Fort Berthold Indian Reservation in North Dakota. The settlement requires that Marathon pay a civil penalty of $64.5M, which the EPA calls "the largest ever for violations of the Clean Air Act at stationary sources," which include facilities such as oil and gas tank systems. Under the settlement agreement, Marathon will implement extensive compliance measures to achieve major reductions in harmful emissions from over 200 facilities across the state. "The agreement requires Marathon to invest in extensive compliance measures estimated to cost $177M, much of which will be implemented by the end of 2024. The settlement requires Marathon to obtain permits with federally enforceable emissions limits at production facilities on the Fort Berthold Indian Reservation and future operations in the state of North Dakota. Compliance measures also include flare monitoring, periodic infrared camera inspections and implementation of storage tank design requirements," the EPA noted. Reference Link

12:25 EDT Tevogen says 'considering available options' including buyback - Tevogen Bio released a letter to stockholders and said it is exploring a potential share buyback. The letter states in part, "Our lead product candidate TVGN 489, an investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocyte immunotherapy, is progressing for the treatment of acute COVID-19 in vulnerable cancer patients. Phase I clinical trial results of TVGN 489, have recently been published by Blood Advances, a peer reviewed journal. A trial aimed at identifying genetic characteristics, potentially leading to Long COVID, has been prepared and could serve as a basis for a later treatment trial...In light of recent stock performance, we understand the concerns some of you may have regarding Tevogen Bio's current share price. We are acutely aware of the situation and our commitment to improving stockholder value remains steadfast. We are considering available options, including the potential for a share repurchase, to enhance the value of your investment."

12:01 EDT ZIM Integrated falls -9.3% - ZIM Integrated is down -9.3%, or -$1.85 to $17.98.

12:01 EDT E2open falls -16.2% - E2open is down -16.2%, or -72c to $3.73.

12:00 EDT QuantumScape rises 28.5% - QuantumScape is up 28.5%, or $1.54 to $6.95.

11:41 EDT Tesla down 5% after report of plans to delay robotaxi reveal event

10:51 EDT GM announces new investments in Lansing Grand River - General Motors stated: For more than 20 years, our GM Lansing Grand River team has built luxury and performance vehicles our customers love, like the Cadillac V-Series Blackwings. Now, we're excited to announce that with a $500 million grant from the U.S. Department of Energy and our own investment, we'll prepare Lansing Grand River for electrification. The grant comes from a federal Domestic Manufacturing Conversion Grant program. These cost-shared grants support U.S. production of efficient hybrid, plug-in electric hybrid, plug-in electric, and hydrogen fuel cell electric vehicles... Lansing Grand River will join other GM plants on our EV journey, including Factory ZERO Detroit-Hamtramck Assembly Center and Orion Assembly in Michigan, Spring Hill Manufacturing in Tennessee, Fairfax Assembly in Kansas and Toledo Propulsion Systems in Ohio. Plus, we continue to invest in an array of GM component, stamping and propulsion plants... Lansing Grand River, represented by UAW Local 652, will continue to produce the Cadillac CT4 and CT5 (including V-Series). We look forward to sharing more details around timing, future products, and volume down the road." Reference Link

10:25 EDT Delta Air Lines CEO: Health of industry in 'pretty good shape'

10:22 EDT Delta Air Lines: July, August 'has never been peak for business'

10:15 EDT Delta sees inflection to positive unit revenue growth in Sept. for domestic

10:11 EDT Delta Air Lines sees June, July as low point for unit trends in Q3 - Sees unit trends significantly improving in August and beyond.

10:00 EDT Barnes & Noble Education rises 12.8% - Barnes & Noble Education is up 12.8%, or 91c to $8.03.

10:00 EDT Methode Electronics rises 30.5% - Methode Electronics is up 30.5%, or $2.88 to $12.31.

10:00 EDT E2open falls -16.2% - E2open is down -16.2%, or -72c to $3.73.

09:48 EDT Barnes & Noble Education rises 13.1% - Barnes & Noble Education is up 13.1%, or 93c to $8.05.

09:47 EDT QuantumScape rises 26.4% - QuantumScape is up 26.4%, or $1.43 to $6.84.

09:47 EDT Amwell falls -9.7% - Amwell is down -9.7%, or -65c to $6.01.

09:33 EDT Trust Stamp onboarded 21 cutsomers to Orchestration Layer platform in 1H24 - Trust Stamp announced that in H1 of 2024 it has onboarded 21 new customers to its low-code Orchestration Layer platform, bringing the total number to 69, while growing its overall financial services customer base in the United States and internationally and increasing the industries served. Trust Stamp President Andrew Gowasack, commented, "We have made tremendous progress building our business in 2024 and I know that it can be frustrating for shareholders who typically see company performance through the short term prism of reported revenue, or the snapshot of individual press releases, therefore I am pleased to provide our shareholders, and the market, with a holistic report on our business achievements for H1 of 2024."

09:22 EDT IMAC Holdings appoints Matthew Schwartz, Peter Beitsch to board - IMAC Holdings announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. Schwartz currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. Beitsch currently serves as the Co-Founder of Targeted Medical Education and The Breast Care Network, as well as Co-PI of the iGAP Registry on the Digital Health Platform at InVitae.

09:18 EDT Del Taco debuts Del's Real Deal$ menu - Del Taco is aiming to deliver on its promise of providing guests with the best quality and value with their NEW Del's Real Deal$ Menu. With a variety of 15 items all available at $2 and under, the new value menu features tacos, burritos, nachos, snacks, and snack-sized chips & fresh house-made guacamole - the newest addition to the value menu. The Del's Real Deal$ Menu provides real ingredients made from scratch at a lower price point. The new menu serves as a testament to the brand's commitment to consistently offer quality menu items that are both budget-friendly and delicious.

09:10 EDT Falcon's Beyond announces Bruce Brown as Chief Legal Officer - Falcon's Beyond Globa is proud to announce the promotion of Bruce A. Brown as the Company's Chief Legal Officer and Corporate Secretary. The newly created role is a promotion for Brown, who has served as Falcon's Executive Vice President of Legal, General Counsel & Corporate Secretary since October 2023. He will continue to report to the Company's President, Simon Philips. "I joined Falcon's Beyond at a pivotal moment in its history, and it's been an exciting ride as we've evolved from a private firm to a public company on the Nasdaq," said Bruce A. Brown. "It has been rewarding to establish the foundation to ensure continued success for our Company and I look forward to helping Falcon's continue to grow and enhance its businesses."

09:08 EDT Nuvei announces partnership with Mastercard - Nuvei (NVEI) announces a partnership with Mastercard (MA) to launch a new off-ramping solution that enables consumers in Europe to seamlessly convert their Digital Assets, including cryptocurrencies, into traditional fiat currency via debit, credit and prepaid cards. This new functionality provides a bridge between digital and traditional finance that can be spent via Mastercard's global network. This off-ramping solution is integrated directly into Nuvei's modular payment platform, delivering a simple, secure user experience.

09:07 EDT Southwest announces new, multi-year sponsorship agreement with SEC Network - Southwest Airlines announces a new, multi-year sponsorship agreement with the Southeastern Conference and SEC Network to be the "Official Airline of the SEC." The deal-officially launched on July 1-will primarily highlight the athletic contributions to SEC football, men's and women's basketball, baseball, softball, gymnastics, and women's soccer. The sponsorship includes integrating Southwest Airlines on SEC Network programming and within the SEC footprint through SEC Nation, the network's traveling football pre-game show. Southwest will also activate on-site at SEC FanFare at the football championship in Atlanta and will have a presence at other major SEC championship events, including women's and men's basketball.

09:07 EDT Progress Software announces new enhancements to Progress LoadMaster 360 - Progress announced new and powerful enhancements in the latest release of Progress LoadMaster 360, its cloud-based unified application delivery platform. These enhancements help organizations protect their web applications against increasingly sophisticated cyberattacks and provide customers with an optimal application experience. With today's release, Progress provides customers with an enhanced Web Application Firewall offering that delivers improved security insights, minimizes the time required for WAF configuration and tuning and easily identifies false positives for legitimate application traffic.

09:06 EDT Check Point announces $2B expansion of share repurchase authoriziation - Check Point Software Technologies announced that its board of directors has authorized a $2.0 billion expansion of the company's on-going share repurchase program. As of June 30, 2024, Check Point had approximately 111 million ordinary shares outstanding, and since the beginning of the share repurchase program, Check Point has repurchased approximately 218 million shares for a total purchase price of approximately $15 billion. The updated plan extends the company's existing repurchase authorization from February 2023, which is expected to be completed during the fourth quarter of 2024.

09:04 EDT Greenidge Generation launches bitcoin mining site in Mississippi - Greenidge Generation announced that it has expanded its bitcoin mining capabilities with the launch of its newest bitcoin mining site located in Mississippi. The site went live on July 1 with 2,400 bitcoin miners that Greenidge deployed from its fleet. In the coming weeks, Greenidge also expects to deploy its first shipment of Antminer S21 Pro bitcoin miners across its active sites to further increase its mining capacity. Greenidge acquired the 12-acre property in Mississippi earlier this year and built out the site utilizing its proprietary Greenidge Pod X, a best-in-class crypto mining infrastructure solution. Greenidge currently has access to 8.5 MW of power at the site and intends to obtain at least 25 MW of additional power within the next 12 months in order to further expand its overall power capacity. In addition, Greenidge expects to finalize the planned lease of the on-site warehouse by September 1.

09:04 EDT Vera Bradley announces brand transformation - Vera Bradley unveiled a full transformation aimed at reinvigorating the business and restoring brand relevance - featuring a new logo, in-store renovations, an optimized website experience, and updated digital channel presence - as well as a new, elevated product line that celebrates customers' unique sense of style and encourages self-expression. The new product assortment, available to shop now, features elevated fabrics and performance materials, such as cotton gabardine, oxford canvas, and genuine full grain leather, and includes an expansion of modernized silhouettes. The new styles have been elegantly redesigned while honoring the heritage and elements that have classically defined Vera Bradley.

09:03 EDT Envestnet signs agreement to be acquired by Bain Capital for $4.5B - Envestnet has entered into a definitive agreement to be acquired by Bain Capital in a transaction valuing the company at $4.5B, or $63.15 per share. Reverence Capital also agreed to participate in the transaction. Strategic partners BlackRock, Fidelity Investments, Franklin Templeton, and State Street Global Advisors have committed to invest in the proposed transaction, and upon its completion they will hold minority positions in the private company. Envestnet shareholders will receive $63.15 in cash for each share of common stock they own. The transaction is expected to close in Q4, subject to the satisfaction of customary closing conditions, including receipt of approval by Envestnet's shareholders and required regulatory approvals. Upon completion of the transaction, Envestnet's common stock will no longer be publicly listed, and Envestnet will become a privately held company. RBC Capital Markets, BMO Capital Markets, Barclays, and Goldman Sachs provided committed debt financing for the transaction and financial advisory services to Bain Capital. Funds managed by Ares Management, funds managed by Blue Owl Capital and Benefit Street Partners also provided committed debt financing for the transaction.

09:02 EDT SuperCom secures additional $2.9M in new orders from European governments - SuperCom is pleased to announce the receipt of new orders from European governments valued at $2.9M. These orders are expected to be delivered in the next four months. This is the third group of orders from European clients in the past 90 days, bringing the total value of new orders from the region to over $11M in this period.

09:02 EDT Heart Test Laboratories announces allowance of U.S. patent for AI-ECG - Heart Test Laboratories announced that intellectual property exclusively licensed to HeartSciences has received a notice of allowance from the United States Patent and Trademark Office for the detection of left ventricular and/or right ventricular dysfunction using deep learning, further strengthening the Company's AI-ECG IP portfolio.

09:01 EDT Clene announces plans to submit briefing book to U.S. FDA - Clene and its wholly owned subsidiary Clene Nanomedicine announced plans to submit a briefing book by July 13 to the U.S. Food and Drug Administration in advance of a granted Type C interaction. The purpose of the interaction with the FDA, to occur in the third quarter of 2024, is to receive feedback on the potential path to submission of a new drug application for CNM-Au8 as a potential treatment for ALS via the accelerated approval pathway. Clene's briefing book contains new post-hoc analyses of data from completed clinical studies and is designed to address comments from the FDA made in a prior meeting announced publicly in December 2023, and in which Clene obtained feedback regarding the potential for accelerated approval. The briefing book contains additional analyses of neurofilament light biomarker reduction, a more matured set of survival and functional benefit data, and additional evidence of CNM-Au8's potential mechanism of action, which Clene believes collectively support accelerated approval based on NfL reduction as a surrogate endpoint.

08:57 EDT Matterport achieves AWS IoT Competency Status - Matterport has achieved Amazon Web Services IoT Competency status. This designation underscores Matterport's pivotal role and expertise in innovative Internet of Things technologies, empowering customers to leverage AWS for IoT and achieve their cloud transformation goals.

08:40 EDT Biodexa announces additional results of Phase 2 trial of eRapa - Biodexa Pharmaceuticals is making good progress with eRapa, its drug to treat Familial Adenomatous Polyposis. FAP is a mostly inherited condition that puts people at a much greater risk of developing colorectal cancer. Positive 12-month data from a phase 2 clinical trial were recently presented at the 2024 InSIGHT biannual meeting in Barcelona. With FAP, hundreds or thousands of precancerous polyps grow throughout the gastrointestinal tract. There is no approved therapeutic option for treating FAP patients - for whom active surveillance and surgical resection of the colon and/or rectum remain the standard of care. People with FAP, which usually appears in the patient's mid-teens, end up eventually having their entire colon and/or rectum resected and having to carry a colostomy bag for the remainder of their lives . If left untreated, there is a 100% chance the person will develop colorectal cancer. Biodexa believes eRapa could be the first therapeutic option to treat this precancerous condition, and its data so far backs up that assessment. Results of a 12-month phase 2 clinical trial of eRapa demonstrated an overall 17% median decrease in overall polyp burden and an overall non-progression rate of 75%. Even more compelling, of patients in Cohort 2, 89% of patients were deemed non-progressors at 12 months, with a median reduction in polyp burden of 29%. That could be gaming-changing for FAP patients if it means fewer surgeries with much improved quality of life. The 12-month data demonstrate a longevity of effect of eRapa. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus, which slows down the mTOR protein. Too much mTOR has been linked to cancer. The phase 2 open-label study of 30 adults with FAP was conducted in seven U.S. centers of excellence. The median age of the trial participants was 43 years, with either an intact colon or one with a portion removed and at least ten noncancerous tumors in the rectal remnant. Patients were enrolled in three dosing cohorts, including every other day, daily every other week and daily. Although the primary endpoints were safety and tolerability of eRapa and percentage change from baseline in polyp burden at six months, patients continued to receive treatment and monitoring for 12 months, leading to the new data. Biodexa said the dosing given to cohort 2 - daily every other week - will likely be the preferred dosage regime for its phase 3 trial, which the company is gearing up to launch soon. That study is planned to be a double-blind placebo-controlled design recruiting approximately 140 high-risk patients diagnosed with germline or phenotypic FAP. Biodexa's phase 2 results were presented at InSIGHT by Carol Burke, M.D., a specialist gastroenterologist at the Cleveland Clinic and a leading authority in FAP. Burke is the Principal Investigator for both the phase 2 study and the upcoming phase 3 study. The phase 2 trial was partially supported by $3 million in grant funding from the Cancer Prevention and Research Institute of Texas. CPRIT is providing a $17 million grant for the phase 3 trial.

08:37 EDT Granite awarded an approximately $20M contract in the Coachella Valley - Granite has been awarded an approximately $20M contract by the Coachella Valley Association of Governments CVAG to construct the next segment of what will ultimately be a 40-mile pathway in Southern California from Palm Springs to Thermal. This project completes segments in the cities of Palm Springs and Cathedral City. Project funding comes from CVAG and will be included in Granite's second-quarter CAP. The multimodal pathway will provide a route for pedestrians, bicyclists, and low-speed electric vehicles, reducing vehicular traffic. This pathway will not only connect communities but also provide residents with an alternative outlet for outdoor activity. Granite successfully constructed an on-street portion of the CV Link in Palm Desert in 2021. This new project aligns Granite's home market strategy, further cementing its position within the Coachella Valley. "Granite has been a proud member of the Coachella Valley community since 1992 and is honored to be a part of this transformative project," said Bill Moore, Granite Vice President of Regional Operations. "We have a long history of constructing projects for both the City of Palm Springs and the City of Cathedral City, and much of our craft workforce that will construct this project resides right here in the Coachella Valley." Granite's Desert Cities Asphalt Plant will supply a portion of the materials for the project. The project is expected to begin in July 2024 and be completed in July of 2025.

08:36 EDT Bigg Digital Assets provides update on Netcoins USA expansion - BIGG Digital Assets provided an update on Netcoins USA's expansion and Sales team hires. Netcoins USA will announce its official USA expansion go-live date this month. To better serve the needs of OTC and Business clients, Netcoins is adding the Web channel to its USA platform, in addition to its Mobile Applications. Netcoins has hired Erin Self and Michael Kitt to join its OTC Sales and Trading team adding more coverage across the Canadian and the US markets. The Netcoins OTC Sales team will be attending Bitcoin 2024 in Nashville, TN. Netcoins continued with its integration with Zero Hash during Q2 per the plan, while continuing to trade in the 16 U.S. states it operates in. Netcoins strategically added several new features in addition to utilizing Zero Hash for licenses and infrastructure as part of its re-launch. As part of the re-launch of Netcoins USA and the growth of the OTC Sales team, Netcoins will be attending Bitcoin 2024 in Nashville Tennessee. Netcoins will be completing the following steps ahead of going live across the United States: Comprehensive testing of all of the integrations and flows with Zero Hash; Migrating existing OTC and Business clients to the Zero Hash-supported platform; Adding additional Liquidity to the platform with new partners; Launching its updated Netcoins USA website; Adding new coins for trading that were not previously available; Implementing dedicated Individual and Business onboarding flows for clients; Launching Netcoins USA on the Web and Mobile.

08:35 EDT Prenetics announces Beckham has become strategic investor in the business - Prenetics announce that David Beckham has become a strategic investor in the business. Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on cutting-edge consumer health products, with details to be announced at a later date. Danny Yeung, CEO and co-founder of Prenetics, welcomed David Beckham's involvement: "This partnership with David marks a transformative era for Prenetics in global health innovation and wellness. David epitomizes the values of discipline, teamwork and health, aligning perfectly with Prenetics' core principles. Working closely with David these past months, I've been consistently inspired by his vision for accessible health for all. His passion and commitment are truly extraordinary. With IM8, we have a unique opportunity to contribute meaningfully to the consumer health and wellness industry."

08:34 EDT Tiber Ventures updates tender offer expiration date - Tiber Ventures announced that its modified "Dutch auction" Tender Offer will be extended for ten business days and will now expire one minute after 4:59 P.M. Eastern Daylight Time on July 25, 2024 unless further extended by Tiber or otherwise terminated. Tenders of shares must be made on or prior to the expiration of the Tender Offer and may be withdrawn at any time prior to the expiration of the Tender Offer, in each case, in accordance with the procedures described in the Tender Offer materials distributed to Tiber's stockholders. The Tender Offer is not conditioned on the receipt of financing or any minimum number of shares being tendered, but it is subject to certain other conditions. Subject to applicable law, Tiber may extend, terminate or otherwise amend the Tender Offer in its sole discretion. The Tender Offer documents contain tendering instructions and a complete explanation of the Tender Offer's terms and conditions. Tiber expects to use cash and cash equivalents to fund the purchase of shares validly tendered and accepted in the Tender Offer. As of 5:00 PM Eastern Daylight Time on July 10, 2024 there have been 153,028 shares tendered and any shares that have been previously tendered may be withdrawn up until the Expiration Time, as so extended.

08:33 EDT Runway Growth Finance funds two investments in Q2 - "Runway Growth delivered portfolio expansion in the second quarter while maintaining our disciplined approach to underwriting and credit quality," said David Spreng, CEO. "As we evaluate the current late- and growth-stage market, we are confident that more high-quality companies are seeking non-dilutive capital to advance their strategic roadmaps. Our borrowers continue to generate strong performance in the existing operating environment, and we look forward to partnering with additional companies. We have a strong, actionable pipeline of attractive investments and believe we are well-positioned to execute on the right transactions in the second half of 2024." In the second quarter of 2024, Runway Growth funded two investments in new portfolio companies. These include: Completion of a $58.4 million investment to a new portfolio company in the marketing technology industry that is an enterprise SaaS platform focused on customer engagement for mobile apps, funding $58.4 million at transaction close; an Completion of a new $56.1 million senior secured term loan commitment to Onward Medical, funding $17.1 million at close. Onward is a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injuries. During the second quarter ended June 30, 2024, Runway Growth experienced one prepayment totaling $25.3 million and scheduled principal amortization of $1.3 million. The prepayment included: Full principal repayment of the Company's senior secured term loan to Turning Tech Intermediate, of $25.3 million.

08:33 EDT Inspira Technologies' ART 100System granted Israeli regulatory approval - Inspira Technologies received the Israeli Ministry of Health's medical devices and accessories approval for the Inspira ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system.

08:31 EDT T. Rowe Price reports preliminary AUM $1.57T as of June 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.57T as of June 30. Preliminary net outflows were $2.6B for June 2024 and $3.7B for the quarter-ended June 2024. Preliminary quarterly net flows include $1.1B of Manager-driven distributions.

08:22 EDT PureCycle, MiniFIBERS, Beverly Knits complete trial with PCR resin - PureCycle Technologies announced a trial run with MiniFIBERS and Beverly Knits, resulting in the production of several high-quality product samples. MiniFIBERS used PureCycle resin produced from post-consumer recycled waste to create fiber packages. These packages were then sent to Beverly Knits and used to produce textiles for a broad range of markets including home goods, automotive applications, industrial solutions, and apparel products. These initial product samples are designed to allow brand owners to feel confident that there will be no compromise in quality when they introduce PureCycle resin into their products.

08:19 EDT Mangoceuticals announces partnership with ISFLST - Mangoceuticals announces that it has secured a strategic partnership with the International Society of Frontier Life Sciences and Technology, ISFLST, for the distribution of its products in China and the Asia Pacific region and Latin America. This agreement marks a significant milestone in MangoRx's expansion strategy, aiming to bring its premier men's health solutions to the rapidly growing markets in these regions. Under this agreement, ISFLST, who has offices in the US, China and South Korea, will leverage its extensive network and expertise to introduce and promote MangoRx's cutting-edge products across Asia and Latin America. The collaboration is designed to enhance brand visibility, drive product adoption, and meet the increasing demand for high-quality men's health products in these areas.

08:17 EDT Olaplex Holdings appoints Dunleavy as COO, CFO, Gohman as CMO - Olaplex Holdings announced the appointment of two highly seasoned leaders to its executive team. Catherine Dunleavy will join OLAPLEX as Chief Operating Officer, COO, and Chief Financial Officer,CFO, effective August 13, and Katie Gohman will join the Company as Chief Marketing Officer, CMO, effective July 15. Most recently, Dunleavy served as President, and, prior to that, as Chief Financial Officer at Away. Gohman most recently served as the CMO at Marc Jacobs.

08:16 EDT Fortrea Holdings appoints Parks as CAO - Fortrea announced that Robert "Bobby" Parks has been appointed as chief accounting officer, CAO, responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. Most recently, Parks served as CAO at SailPoint Technologies Holdings, a leader in identity security software.

08:14 EDT Genasys announces Singapore Changi Airport ordered additional LRAD systems - Genasys announced a new LRAD systems order from Singapore Changi Airport. Changi has used Genasys' Long Range Acoustic Devices since 2021 to prevent birds from hitting planes and passenger jets during takeoffs and landings when aircraft are most vulnerable to bird strikes. "In addition to LRAD deployments at Changi and other APAC airports, we are working several pipeline opportunities to protect jets, passengers and wildlife in the APAC and European regions," said David Schnell, VP Global Hardware Sales at Genasys. "Manually operated or integrated with remote command and control centers, LRAD is a humane bioacoustic deterrent that has proven highly effective in preventing aircraft bird strikes near runways."

08:13 EDT Palisade Bio announces completion of first GMP batch of PALI-2108 - Palisade Bio announced the successful completion of the first Good Manufacturing Practice, GMP, batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization. This partnership included process development and scale-up of PALI-2108 to ensure adherence to regulatory standards. The drug substance produced has been successfully implemented in the Company's completed murine and non-murine GLP toxicology studies and is slated for use in its upcoming Phase 1 clinical study. In addition to the successful production of the drug substance, Palisade has completed manufacturing and performance testing of engineering batches of the drug product.

08:12 EDT Enphase announces residential, commercial products to help solar projects - Enphase Energy announced residential and commercial products that can help solar projects qualify for the "Domestic Content Bonus Credit." Projects using specific Enphase microinverters supplied from manufacturing partners in the United States and specific U.S.-made solar racking equipment could qualify. The Domestic Content Bonus Credit is a tax credit that aims to encourage manufacturing and clean energy deployments in the United States as part of the Inflation Reduction Act, IRA.

08:11 EDT Acumen will present patient experience, data from Phase 1 INTERCEPT-AD study - Acumen Pharmaceuticals announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug at the Alzheimer's Association International Conference, AAIC, 2024 taking place in Philadelphia and online from July 28 - Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid, and provide insights on patients' experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug. Sabirnetug is the first humanized monoclonal antibody to demonstrate in patients with early symptomatic AD selective target engagement of AbetaOs, a soluble and highly toxic form of Abeta that accumulates early in AD and is a persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early symptomatic AD.

08:10 EDT GSK begins shipping doses of its trivalent influenza vaccines in U.S. - GSK announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration FDA. In February 2024, the World Health Organization WHO recommended the removal of B/Yamagata strains from seasonal influenza vaccines... The WHO recommends that egg-based trivalent vaccines for the 2024-2025 northern hemisphere influenza season... In partnership with regulatory bodies, GSK worked quickly to ensure production, approval and availability of trivalent influenza vaccines with the recommended composition for the 2024-25 flu season. GSK expects to distribute over 36 million doses of its trivalent influenza vaccines in the US this season. Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months of age and older.

08:07 EDT Inovio's INO-3107 awarded Innovation Passport designation in the U.K. - Innovio's lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway - ILAP -. The designation, called an Innovation Passport, was granted by the ILAP Steering Group to INO-3107 for the treatment of patients with Recurrent Respiratory Papillomatosis or RRP, a debilitating, chronic rare disease of the respiratory tract caused by HPV-6 and/or HPV-11. The Innovation Passport is the entry point to the ILAP, which aims to accelerate time to market and facilitate patient access to medicines in the United Kingdom. The Innovation Passport provides a single, streamlined roadmap for regulatory approval and development milestones.

08:07 EDT Talkspace, Wellbeing at Work announce strategic partnership - Talkspace and Wellbeing at Work announced a strategic partnership. This collaborative integration offers Talkspace's comprehensive digital mental health services within Wellbeing at Work's innovative benefits navigation platform, leveraging Gallup's science of wellbeing.

08:06 EDT Lexeo Therapeutics to report interim Phase 1/2 clinical data of LX2006 - Lexeo Therapeutics announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical trial and the ongoing Weill Cornell Medicine investigator-initiated trial, as well as an overview of program next steps.

08:06 EDT ChargePoint says Mansi Khetani appointed CFO - ChargePoint announced the appointment of a Chief Financial Officer, Chief Development Officer for Software, and a new member of the Board of Directors . All three individuals join ChargePoint with the skillset, passion, and experience to continue accelerating ChargePoint's leadership position in the electrification of transportation. "I am thrilled to have this trio of potent leaders as part of the ChargePoint team. Each brings unique capabilities that will help us continue to make ChargePoint the platform of choice for everyone who wants to offer EV charging and they share a deep passion to build something that is better than all other alternatives. There is almost no limit to the potential of a company that recruits great people, and these three additions to our team are as great as they get," said Rick Wilmer CEO of ChargePoint. Mansi Khetani has been appointed Chief Financial Officer, effective July 9, Ms. Khetani has been with ChargePoint since 2018, previously leading Financial Planning and Analysis efforts before becoming interim CFO in November 2023. She has extensive experience spanning financial planning, corporate development, M&A, and investment banking. Ms. Khetani previously held senior corporate positions at Gainsight and Rocket Fuel, and senior investment banking positions at Piper Jaffray and Merrill Lynch. Mansi holds an M.B.A. and is a Chartered Accountant. Ash Chowdappa has joined ChargePoint as Chief Development Officer for Software, where he will lead the Software team across all regions, products, and segments. Mr. Chowdappa is a seasoned technology veteran that has been in customer and field facing business leadership roles for nearly 25 years.Mitesh Dhruv has joined ChargePoint's Board and will serve as a member of the Audit Committee.

08:05 EDT Catapult Group, USA Volleyball extend partnership - Catapult announced an extension of its strategic partnership with USA Volleyball. This partnership marks a significant milestone in training men and women athletes for indoor, sitting, and beach volleyball. Catapult has provided USA Volleyball national teams, as they prepare for the 2024 Summer Olympics in Paris, with innovative athlete monitoring technology to improve performance, reduce the risk of injuries, and accelerate return to competition from injury.

08:05 EDT Criteo announces strategic collaboration with Microsoft Advertising - Criteo (CRTO) announced a strategic collaboration with Microsoft (MSFT) Advertising to bring Microsoft Advertising's extensive demand to Criteo's global network of 225 retailers. Microsoft Advertising also intends to work with Criteo as its preferred onsite media partner, extending Criteo's monetization technology to Microsoft Advertising's retailer clients, creating an even more unified retail media ecosystem.

08:04 EDT FuelCell holds event in South Korea on accelerating energy transition - FuelCell Energy held a pivotal event in Seoul on June 28, 2024, reinforcing and demonstrating the company's commitment to the Korean market and highlighting how its two differentiated carbonate and solid oxide platforms enable the energy transition to sustainable energy in a smart and practical way. The event, titled "Accelerating Korea's Energy Transition with Advanced Fuel Cell Solutions," showcased FuelCell Energy's cutting-edge technology and strategic vision for the nation's energy future. The gathering was attended by leaders of the Korean energy industry and FuelCell Energy executives, including the company's new General Manager for Korea, YoungKyoo Peter Han. FuelCell Energy executives and experts, Mark Feasel and Anthony Leo, delivered a presentation on fuel cell technology's critical utility for the energy transition. CEO Andy Kim of Gyeonggi Green Energy and CEO Chang Suk Ko of Nouel Green Energy, two of FuelCell Energy's customers, also addressed the group to provide their perspective on FuelCell Energy's fuel cell technology platforms and how they support the needs of their businesses and commitment toward decarbonization. FuelCell Energy President and CEO Jason Few said, "We were extremely pleased with the interest and reception from our energy industry counterparts in Korea and look forward to growing our market there following 20 years of supplying carbonate fuel cells to our generation, commercial and industrial company partners in the Asia region."

08:03 EDT Nut Tree, Caspian propose to acquire Martin Midstream Partners for $4.00/unit - Nut Tree Capital and Caspian Capital announced they sent a letter to the Conflicts Committee of the Board of Directors of Martin Midstream GP in which Nut Tree and Caspian reiterated their non-binding proposal made on June 21, 2024 to acquire Martin Midstream Partners L.P. for $4.00 per MMLP common unit in cash. The Proposal represents a 31% premium over the $3.05 per common unit offer made by Martin Resource Management Corporation on May 24, 2024, and 23% over the closing price of the common units on July 9, 2024. The Proposal is not subject to any financing condition and would be financed through capital on hand. As existing investors in the MMLP's debt, and given their significant experience investing in the oil and gas sectors, Nut Tree and Caspian are already very familiar with MMLP, its operations and capital structure, and have reviewed all publicly available information regarding MMLP.

07:47 EDT Jacobs selected by Omaha, NE, Streetcar Authority for transportation project - Jacobs was selected as Owner's Representative for the Omaha Streetcar Authority's streetcar project, which will establish transportation options and attract new growth in Omaha's urban core. Jacobs' services will include design review, delivery oversight, and management of project budget and schedule. Omaha streetcars will run on electricity.

07:35 EDT Conagra Brands sees FY25 CapEx ~$500M - Sees FY25 Net Leverage Ratio of approximately 3.2x; Adjusted effective tax rate of approximately 23.5%.

07:34 EDT Dorman Products announces new releases for July - Dorman Products is announcing the release of hundreds of new aftermarket automotive components and assemblies. Adding to an expansive catalog of more than 122,000 SKUs, the July 2024 new product releases represent millions of new sales opportunities for automotive and heavy-duty parts distributors, retailers and repair shops, reinforcing Dorman's position as a premier go-to source for technicians and dedicated DIYers.

07:33 EDT Avicanna subsidiary completes export of Aureus branded products into Singapore - Avicanna, through its majority-owned subsidiary Santa Marta Golden Hemp, completed the commercial export of Aureus branded products into Singapore. The commercial export included Aureus branded purified Cannabigerol which is a part of the Company's portfolio of cannabinoid active pharmaceutical ingredients. This transaction also marks the 18th international market for Aureus-branded products, first export into Asia and 21st market for all Avicanna products which further validates the Company's expertise in navigating complex regulatory processes for its commercialization efforts internationally.

07:32 EDT Danaher launches collaboration for smart microscope development - Danaher launched a research collaboration with Stanford University's Department of Bioengineering intended to shape the future of cancer drug screening through "smart microscopy." Combining spatial biology with artificial intelligence, the research team at the Danaher Beacon for Spatialomics aims to help de-risk cancer drug development. The collaboration aims to leverage the latest findings in spatial biology coupled with AI to make it possible to screen more complex cellular systems. The collaboration is a partnership between Leica Microsystems, a Danaher subsidiary, and Lundberg, a researcher in the field of spatial proteomics and cell biology known for her involvement in the Human Protein Atlas project. The collaboration is the latest addition to the Danaher Beacons program, which funds product-driven scientific research with globally recognized academic investigators.

07:25 EDT Lithium Ionic files NI 43-101 technical report for Bandeira Lithium study - Lithium Ionic has filed the independent NI 43-101 compliant technical report for its Bandeira Lithium Project in Minas Gerais State, Brazil, supporting and validating the Feasibility Study) results press released on May 29, 2024. The Technical Report details a feasibility study that supports a robust project with strong economic viability, featuring a small footprint underground mine, an efficient and straightforward processing circuit, and a safe, sustainable dry stack tailings facility. Highlights of the FS are as follows: 14-year mine life producing an average of 178,000tpa of spodumene concentrate; After-tax NPV8 of US$1.3B; IRR of 40%; Industry-leading LOM operating costs of $444/t SC5.5; Low CAPEX of $266 million.

07:21 EDT Skillsoft announces $10M share repurchase program - The company also announced that its board of directors has authorized and approved a share repurchase program for up to $10M of the company's outstanding shares of Class A common stock, with an objective to manage potential dilution from future vesting of employee equity grants.

07:13 EDT Electrovaya's high voltage battery system passes fire propagation testing - Electrovaya completed and passed fire propagation testing on two of its high voltage battery systems, each with over 50kWh in capacity. The testing was done in accordance with the UL2580 standard and one test was completed at an independent lab and the second completed in-house. This testing involved forcing a single cell in the battery system to thermal runaway through directly heating a cell. The passing result was the fire remained contained and did not spread within or outside of the battery system. A "real world" comparison would be if there was a fire within the battery system at a single cell level, but did not propagate and lead to a further fire. From the Company's understanding, in most cases, this type of scenario with competing battery suppliers would lead to large and well documented battery fires.

07:11 EDT Virtus Investment reports total client assets of $176.2B as of June 30 - Virtus Investment Partner reported preliminary assets under management or AUM of $173.6B and other fee earning assets of $2.6B for total client assets of $176.2 B as of June 30. The decrease in AUM from March 31, 2024 primarily reflects market performance and net outflows due to institutional accounts and open-end funds, partially offset by positive net flows in retail separate accounts. Preliminary average AUM for the quarter was $175.2B.

07:09 EDT NFI's Alexander Dennis receives order from Stagecoach for 41 buses - NFI Group's Alexander Dennis announced the first order from London Operator Stagecoach for 41 next-generation electric buses. Stagecoach will receive 24 Enviro100EV small buses and 17 Enviro400EV double deckers in early 2025 for routes operated on behalf of the British capital's transport authority Transport for London.

07:09 EDT Renalytix announces collaboration with Steno Diabetes Center - Renalytix announces a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease, DKD. The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will investigate core elements necessary for successful clinical translation of KidneyIntelX in a European context, beginning with integration of the biomarker testing into laboratory workflows, education of clinicians and patients on the role of KidneyIntelX risk assessment in the continuum of care and, leveraging of electronic health record systems for efficient, risk-based care management. Importantly, this is expected to launch the first use of Renalytix's KidneyIntelX platform outside the US to showcase the clinical utility in the EU by utilizing advanced technology to provide better informed care for solving chronic kidney disease.

07:08 EDT Skye Bioscience establishes metabolic clinical, scientific advisory board - Skye Bioscience announced the formation of its clinical advisory board, CAB, gathering renowned academics and world-class metabolic disease experts, particularly in the field of obesity. The CAB will work closely with management to provide strategic and scientific counsel to support the development of the Company's lead candidate, Nimacimab, a cannabinoid 1 receptor inhibitor, which is expected to enter a Phase 2 trial in individuals with obesity in Q3 2024. Members of the Clinical and Scientific Advisory Board include: Lee Kaplan, MD, Ph.D., Louis Aronne, MD, Rekha Kumar, MD, M.S., Marcus DaSilva Goncalves, MD, Ph.D., Beverly Tchang, MD, Eduardo Munoz, MD, Ph.D., Giovanni Appendino, Ph.D.

07:07 EDT Coeur Mining reports Rochester silver, gold mine completes ramp-up activities - Coeur Mining reported that its recently-expanded Rochester silver and gold mine in Nevada successfully completed ramp-up activities at the end of the second quarter by achieving daily throughput rates of over 88,000 tons per day. Approximately 4.3M tons of ore were placed on the new Stage 6 leach pad during the second quarter bringing the total tons placed to 15.5M tons. Crushing and placement rates were lighter than initially planned during the second quarter while mining rates exceeded plan. Down days taken during the second quarter have Rochester positioned to deliver crushing and placement rates of 7M-8M tons per quarter during the second half of the year and into 2025. At full capacity, throughput levels are expected to be approximately 2.5 times higher than historical levels, or approximately 32M tons per year.

07:07 EDT Can-Fite BioPharma applies for FDA Orphan Drug Designation for namodenoson - Can-Fite BioPharma has submitted an application to the U.S. Food and Drug Administration for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma. Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least first line therapy. The trial will evaluate the safety, clinical activity, and pharmacokinetics of Namodenoson in this population. All patients will receive oral Namodenoson 25 mg administered twice daily for consecutive 28-day cycles. Patients will be evaluated regularly for safety. Approximately 20 evaluable patients will be enrolled. The primary objective of this trial is to characterize the safety profile of Namodenoson and the secondary objective is to evaluate the clinical activity as determined by the Objective Response Rate using Response Evaluation Criteria in Solid Tumors, Progression-Free Survival, Disease Control Rate, Duration of Response (DoR), and Overall Survival. Can-Fite has already been granted Orphan Drug Status for Namodenoson for the indication of advanced liver cancer by the FDA and also by the EMA.

07:05 EDT VNET Group receives withdrawal of non-binding going-private transaction offer - VNET Group announced that the special committee of the company's board of directors received a letter dated July 10 from Josh Sheng Chen, Founder, Co-Chairperson and interim CEO of VNET, stating that Chen had determined not to proceed with his preliminary non-binding proposal dated September 13, 2022 to acquire all of the outstanding ordinary shares of the company and the Founder Proposal was withdrawn with immediate effect. The board of directors approved to dissolve the Special Committee accordingly.

07:03 EDT Sono-Tek sees 2025 capex $300,000 - $350,000 - Capital expenditures in the first quarter totaled $33,000 which were directed to ongoing upgrades to the Company's manufacturing facilities. Sono-Tek anticipates total capital expenditures will be approximately $300,000 - $350,000 in fiscal 2025.

07:01 EDT Cara Therapeutics announces exploration of strategic alternatives - Cara Therapeutics has engaged Piper Sandler & Co. to act as its financial advisor for the process of exploring and reviewing strategic alternatives. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or as to the timing of any such agreements or transactions. Cara Therapeutics does not intend to discuss or disclose further developments regarding the exploration of strategic alternatives unless and until its Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate or required by law. As of March 31, 2024, the Company had approximately $70 million in cash, cash equivalents, and marketable securities.

06:52 EDT MAG Silver says exploration operations at Deer Trail Project temporarily paused - MAG Silver reports that its Deer Trail Project in central Utah is being affected by the Silver King Fire in Piute County. In an abundance of caution, exploration operations at the Deer Trail Project have been temporarily paused, with all personnel safe and the Deer Trail site secure. MAG will continue to carefully monitor the situation and comply with all local directives. The company does not expect this temporary pause in operations to have a material impact on the business.

06:51 EDT NanoViricides provides update on development program for NV-387 - NanoViricides discussed its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications. There are several viruses that continue to cause epidemics in humans; seasonal epidemics with Influenza, RSV, and SARS-CoV-2 are occurring every year. The company said the potential for severe Bird Flu pandemic, that may even be worse than the COVID-19 outbreak, is increasing every year as the virus spreads further into mammals and mutates more, according to experts. Recently a fifth human case of H5Nx "Bird Flu" infection in the USA, acquired at work with infected dairy cattle, was found in Colorado. The person exhibited conjunctivitis symptoms, was given Tamiflu, and has recovered, according to the Colorado Department of Public Health and Environment, or CDPHE. The risk to humans in general remains low, because this bird flu virus has not yet acquired the ability for human-to-human transmission, according to scientists. However, H5N1 bird flu is now widespread in wild birds, and has infected and spread in many mammals, including dairy cattle. The company said, "We have started planning Phase II clinical studies of NV-387 as a treatment for RSV and other indications including Influenza and COVID, as the Phase I clinical trial comes to a close. We plan on taking the drug NV-387 forward on the fastest regulatory path feasible towards regulatory approvals in different countries and jurisdictions including the USA."

06:46 EDT Lazard reports preliminary AUM $244.7B as of June 30 - Lazard reported that its preliminary assets under management, as of June 30, totaled approximately $244.7B. The month's AUM included market appreciation of $2.5B, net outflows of $1.4B and foreign exchange depreciation of $1.4B. Preliminary average AUM for the quarter ended June 30 was $245.3B.

06:40 EDT Nuvalent promotes Henry Pelish to chief scientific officer - Nuvalent announced that Henry Pelish has been promoted to chief scientific officer. In this role, Pelish will continue to oversee discovery and early-stage development activities. Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the discovery and early-stage development of zidesamtinib, NVL-655 and NVL-330 and ongoing research and discovery efforts.

06:32 EDT ITT announces strategic commercial agreement from its Svanehoj business - ITT announced a strategic commercial agreement from its Svanehoj business, furthering the company's leadership position in the green energy transition. Svanehoj, acquired in January 2024 by ITT, is a designer and manufacturer of specialized cryogenic deepwell and submersible pumps for the marine sector. Svanehoj will provide deepwell ammonia fuel pumps for eight bulk carriers owned by a leading maritime shipping and logistics group as part of the contract. The pumps will deliver a highly reliable supply of fuel and are fully compatible with all liquefied gas fuels, including liquefied natural gas, liquefied petroleum gas, methanol and ammonia. This will drive long-term growth as sustainable fuels are widely adopted to reduce greenhouse gas emissions. The first two Svanehoj pumps will be delivered in 2024 with the remainder of the order fulfilled in 2025. The bulk carriers are the first commercial vessels of this size capable of being powered by ammonia. They will be equipped with a dual fueling system: a traditional diesel oil system and a clean fuel system. Svanehoj fuel pumps will future-proof the vessels to handle ammonia and other sustainable fuels.

06:08 EDT Akebia, CSL Vifor enter termination agreement of the Vafseo license agreement - Akebia Therapeutics announced key updates pertaining to the commercial launch of VafseoTablets. Akebia will host an investor conference call at 8:00 a.m. ET on Thursday, July 11. Akebia and CSL Vifor have entered into a termination agreement of the license agreement providing for the payment of royalties by Akebia to CSL Vifor on Vafseo U.S. net product sales. As a result, Akebia regained full rights to sell Vafseo in the U.S. and is able to contract directly with all dialysis organizations effective immediately. Akebia believes its existing and well-established renal sales and medical affairs teams are equipped to drive prescriber demand and enable dialysis organization contracting. Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450M to a mid-single digit percentage on annual net sales above $450M. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450M and eliminate the royalty payment on annual net sales above $450M. In June, Akebia submitted its TDAPA application. Akebia expects to have Healthcare Common Procedure Coding System, or HCPCS, codes assigned in October and full TDAPA designation by January 1, 2025. Vafseo WAC has been set at $1,278 for a 30-day supply at the minimum starting dose, or approximately $15,500 per year. The entire dialysis business will be a contracted business, offering an off-invoice discount as well as volume tier discounts off this WAC price. The potential label expansion into non-dialysis patients was an important factor in determining the WAC pricing for Vafseo.

06:04 EDT KBR awarded $52M IAC MAC task order - KBR was awarded an estimated $52M, 60-month cost-plus-fixed-fee recompete Information Analysis Center Multiple Award Contract, or IAC MAC, task order supporting the Counter Improvised Threat Systems Test and Evaluation for the Naval Air Warfare Center Weapons Division, or NAWCWD, Quick Reaction Capability Office, or QRCO. Under the terms of the contract, KBR will mitigate improvised threats by research, conducting analysis, and using test and evaluation to provide timely and affordable quality data products. The scope of work includes requirements analysis; quick reaction test planning, execution and reporting; prototyping, data acquisition and analysis; engineering, technical and administrative analysis; T&E methodology development; continuous evaluation of evolving test methodologies; and representative test environment design, development and sustainment.

06:01 EDT Sportradar, UEFA extend and expand partnership - Sportradar Group and European Football governing body UEFA have announced a multi-year extension of their existing exclusive betting data rights agreement, expanded to include the non-exclusive right to distribute data to non-betting media. Additionally, the agreement provides Sportradar access to certain advanced tracking. This enriched data will enhance Sportradar's cutting-edge AI products and services, enabling Sportradar to deliver innovative technology solutions to its clients. The agreement covers all UEFA Club and National team competitions. These include the UEFA Champions League, UEFA Super Cup, UEFA Europa League, UEFA Conference League, UEFA Women's Champions League, UEFA Women's EURO 2025, the European Qualifiers to the 2026 FIFA World Cup, the European Qualifiers to UEFA EURO 2028, the UEFA Nations League, the 2025 & 2027 UEFA European Under-21 Championships, and UEFA international friendly matches. In total, Sportradar can now offer more than 900 high-profile matches each season, marking a nearly 33% increase from the previous cycle as a result of the new formats which will be introduced for UEFA Club Competitions at the start of the 2024-25 season. UEFA and Sportradar will also extend their long-standing integrity partnership of 15 years. To support UEFA's Anti Match-Fixing Unit, the cooperation includes dedicated intelligence and investigation resources, robust and systematic bet monitoring, and education services to support the prevention, detection and investigation of match-fixing.

05:29 EDT White Diamond Research issues cautious research note on Agba Group - White Diamond Research issued a new research note on Agba Group, saying that the $4B valuation for the merger between the company and social media company Triller is a "made-up number that is far from reality." Before the merger announcement, White Diamond alleges that Triller and AGBA were both failed, almost bankrupt, companies with little to no value and argues that there is "no logical business" reason for AGBA and Triller to merge, as they are in different sectors with zero synergies, and "both have proven incompetent management." Further, White Diamond claims that Agba's deal with "predatory" lender Yorkville has "terrible" terms for its investors. Reference Link

05:07 EDT Arbe Robotics enters collaboration with European truck manufacturer - Arbe Robotics announced a collaboration with a European truck manufacturer to integrate Arbe's automotive grade imaging radar technology into the manufacturer's next-generation sensor suite, as part of the manufacturer's transition to an advanced implementation stage.